Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 7, 2012, Pages 1569-1577

  Livermore, David M ^a,b   Andrews, Jenny M ^c   Hawkey, Peter M ^d   Ho, Pak Leung ^e   Keness, Yoram ^f   Doi, Yohei ^g   Paterson, David ^h   Woodford, Neil ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f HAEMEK MEDICAL CENTER   (Israel)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Ceftazidime; Clinical Laboratory Standards Institute; CLSI; CTX M lactamases; EUCAST; European Committee on Antimicrobial Susceptibility Testing; KPC lactamases

Indexed keywords

AGAR; AZTREONAM; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFEPIME; CEFMETAZOLE; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM;

ACCURACY; AGAR MEDIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL PERITONITIS; BACTERIAL STRAIN; DEVICE INFECTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; EMPYEMA; ENZYME ACTIVITY; ENZYME ANALYSIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INFECTION; KLEBSIELLA INFECTION; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MEDIASTINITIS; MEDICAL INFORMATION; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERITONITIS; PNEUMONIA; PRACTICE GUIDELINE; PROGNOSIS; PROTEUS; PSEUDOMONAS INFECTION; PYELONEPHRITIS; SURGICAL INFECTION; TRACHEOBRONCHITIS; TREATMENT OUTCOME; URINARY TRACT INFECTION; UROSEPSIS;

ANIMALS; BACTERIA; BACTERIAL INFECTIONS; BETA-LACTAMASES; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84862657112     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks088     Document Type: Article

References (40)

1. Anon. Detection of extended-spectrum β-lactamases (ESBLs) in E. coli and Klebsiella spp. http://www.bsac.org.uk/resources/bsac/ecoliklebsiella. pdf (3 January 2012, date last accessed).
2. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
3. Leclercq R, Canton R, Giske CG et al. Expert Rules in Antimicrobial Susceptibility Testing. http://www.eucast.org/fileadmin/src/media/PDFs/ 4ESCMID_Library/3Publications/EUCAST_Documents/Other_Documents/ EUCAST_Expert_rules_final_April_20080407.pdf (3 January 2012, date last accessed).
4. Leclercq R, Canton R, Brown DF et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 2011; doi:10.1111/j.1469-0691.2011.03703.x.
5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20. CLSI, Wayne, PA, USA, 2010.
6. Andes D, Craig WA. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 2005; 11 Suppl 6: 10-7.
7. Maglio D, Ong C, Banevicius MA et al. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-blactamase-producing Escherichia coli at various inocula. Antimicrob Agents Chemother 2004; 48: 1941-7.
8. Paterson DL, Ko WC, Von Gottberg A et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12.
9. Daikos GL, Petrikkos P, Psichogiou M et al. Prospective observational study of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009; 53: 1868-73.
10. Livermore DM. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36: 2046-8.
11. Katsanis GP, Spargo J, Ferraro MJ et al. Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum β-lactamases. J Clin Microbiol 1994; 32: 691-6.
12. Williamson DA, Roberts SA, Smith M et al. High rates of susceptibility to ceftazidime among globally prevalent CTX-M-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria. Eur J Clin Microbiol Infect 2011; doi:10.1007/s10096-011-1380-1.
13. Hawkey PM. Prevalence and clonality of extended-spectrum β-lactamases in Asia. Clin Microbiol Infect 2008; 14 Suppl 1: 159-65.
14. Diaz MA, Hernandez-Bello JR, Rodriguez-Bano J et al. Diversity of Escherichia coli strains producing extended-spectrum β-lactamases in Spain: second nationwide study. J Clin Microbiol 2010; 48: 2840-5.
15. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74.
16. Woodford N, Ward ME, Kaufmann ME et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother 2004; 54: 735-43.
17. Rooney PJ, O'Leary MC, Loughrey AC et al. Nursing homes as a reservoir of extended-spectrum β-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother 2009; 64: 635-41.
18. Bush K. Extended-spectrum β-lactamases in North America, 1987-2006. Clin Microbiol Infect 2008; 14 Suppl 1: 134-43.
19. Kitchel B, Rasheed JK, Endimiani A et al. Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2010; 54: 4201-7.
20. Koh TH, Sng LH, Babini GS et al. Carbapenem-resistant Klebsiella pneumoniae in Singapore producing IMP-1 β-lactamase and lacking an outer membrane protein. Antimicrob Agents Chemother 2001; 45: 1939-40.
21. Grundmann H, Livermore DM, Giske CG et al. Carbapenem-nonsusceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010; 15: pii=19711.
22. Anderson KF, Lonsway DR, Rasheed JK et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 2007; 45: 2723-5.
23. Bin C, Hui W, Renyuan Z et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 2006; 56: 351-7.
24. Ho PL, Chan WM, Tsang KW et al. Bacteremia caused by Escherichia coli producing extended-spectrum β-lactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis 2002; 34: 567-73.
25. Weisenberg SA, Morgan DJ, Espinal-Witter R et al. Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn Microbiol Infect Dis 2009; 64: 233-5.
26. Jones RN, Barry AL, Thornsberry C. Disk agar diffusion susceptibility testing with 30-mg ceftazidime disks: confirmation of interpretive breakpoints and quality control guidelines. J Clin Microbiol 1983; 18: 211-4.
27. Lat A, Clock SA, Wu F et al. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest. J Clin Microbiol 2011; 49: 1795-8.
28. Giakkoupi P, Tzouvelekis LS, Daikos GL et al. Discrepancies and interpretation problems in susceptibility testing of VIM-1-producing Klebsiella pneumoniae isolates. J Clin Microbiol 2005; 43: 494-6.
29. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011; 35: 736-55.
30. Kitchel B, Rasheed JK, Patel JB et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009; 53: 3365-70.
31. Queenan AM, Foleno B, Gownley C et al. Effects of inoculum and β-lactamase activity in AmpC- and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol 2004; 42: 269-75.
32. Livermore DM, Hope R, Brick G et al. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008; 62 Suppl 2: ii41-54.
33. Ho P-L, Lai EL, Chow KH et al. Effect of applying the new CLSI imipenem susceptibility breakpoints for Enterobacteriaceae in Hong Kong. J Antimicrob Chemother 2011; 66: 2671-3.
34. Potron A, Kalpoe J, Poirel L et al. European dissemination of a single OXA-48-producing Klebsiella pneumoniae clone. Clin Microbiol Infect 2011; 17: E24-6.
35. Xiong J, Hynes MF, Ye H et al. blaIMP-9 and its association with large plasmids carried by Pseudomonas aeruginosa isolates from the People's Republic of China. Antimicrob Agents Chemother 2006; 50: 355-8.
36. Peleg AY, Franklin C, Bell JM et al. Dissemination of the metallo-β-lactamase gene blaIMP-4 among Gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis 2005; 41: 1549-56.
37. Paul M, Shani V, Muchtar E et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010; 54: 4851-63.
38. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60: 913-20.
39. Livermore DM, Warner M, Mushtaq S. Evaluation of the chromogenic Cica-β-Test for detecting extended-spectrum, AmpC and metallo-β-lactamases. J Antimicrob Chemother 2007; 60: 1375-9.
40. Naas T, Cuzon G, Truong H et al. Evaluation of a DNA microarray, the check-points ESBL/KPC array, for rapid detection of TEM, SHV, and CTX-M extended-spectrum β-lactamases and KPC carbapenemases. Antimicrob Agents Chemother 2010; 54: 3086-92.